Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

This study is testing a new type of immune cell therapy called "universal CAR-T" cells — specially engineered immune cells designed to recognize and attack a protein (CD19) found on B-cell lymphoma tumors. Unlike standard CAR-T therapy made from each patient's own cells, this version uses donor-derived cells that can be used off-the-shelf. **You may be eligible if...** - You are between 3 and 70 years old - You have been diagnosed with B-cell lymphoma with CD19-positive tumors - Your lymphoma has come back or stopped responding to at least 2 lines of standard treatment - You have at least one measurable tumor visible on scans **You may NOT be eligible if...** - Your lymphoma has not progressed or relapsed as defined by standard criteria - You had a relapse more than 12 months after a stem cell transplant (specific timing rules apply) - Your disease does not have a measurable lesion on imaging - You have other serious medical conditions that would make participation unsafe Talk to your doctor to see if this trial is right for you.